← Back to Screener
GeneDx Holdings Corp. Class A Common Stock (WGS)
Price$52.00
Value ScoreF
Growth ScoreB
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-77.16%
Price vs S&P 500 (4W)-25.45%
VGM Score39.92
Market Capitalization$1.45B
All Metrics
P/CF (Annual)43.68x
Book Value / Share (Quarterly)$8.57
P/TBV (Annual)26.91x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)22.13%
Cash Flow / Share (Quarterly)$-0.97
Price vs S&P 500 (YTD)-70.96%
Gross Margin (TTM)69.56%
Net Profit Margin (TTM)-17.58%
EPS (TTM)$-2.67
10-Day Avg Trading Volume1.38M
EPS Excl Extra (TTM)$-2.67
Revenue Growth (5Y)18.98%
EPS (Annual)$-0.73
ROI (Annual)-5.55%
Gross Margin (Annual)69.74%
Net Profit Margin (5Y Avg)-91.68%
Cash / Share (Quarterly)$5.75
P/E Basic Excl Extra (TTM)1216.10x
Revenue Growth QoQ (YoY)17.38%
ROA (Last FY)-4.01%
Revenue Growth TTM (YoY)34.09%
EBITD / Share (TTM)$-1.92
ROE (5Y Avg)-76.97%
Operating Margin (TTM)-16.39%
Cash Flow / Share (Annual)$0.49
P/B Ratio5.72x
P/B Ratio (Quarterly)7.40x
Net Income / Employee (Annual)$-16,200
EV / Revenue (TTM)3.29x
Net Interest Coverage (TTM)-7.32x
ROA (TTM)-15.66%
EV / EBITDA (TTM)4057.30x
EPS Incl Extra (Annual)$-0.73
Current Ratio (Annual)2.46x
Quick Ratio (Quarterly)2.84x
3-Month Avg Trading Volume1.07M
52-Week Price Return-25.71%
EV / Free Cash Flow (Annual)102.13x
P/E Incl Extra (TTM)1216.10x
Revenue / Employee (TTM)$340,500
Tangible BV / Share (Quarterly)$3.68
P/S Ratio (Annual)3.40x
Asset Turnover (Annual)0.82x
52-Week High$170.87
Operating Margin (5Y Avg)-119.21%
EPS Excl Extra (Annual)$-0.73
CapEx CAGR (5Y)-9.87%
26-Week Price Return-61.23%
Quick Ratio (Annual)2.27x
13-Week Price Return-36.11%
Total Debt / Equity (Annual)0.23x
Current Ratio (Quarterly)3.09x
Enterprise Value$1.46B
Revenue / Share Growth (5Y)-9.73%
Asset Turnover (TTM)0.89x
Revenue / Employee (Annual)$328,900
Inventory Turnover (Annual)10.52x
Pretax Margin (Annual)-4.94%
Cash / Share (Annual)$5.86
3-Month Return Std Dev123.72%
Gross Margin (5Y Avg)31.71%
Net Income / Employee (TTM)$-59,900
ROE (Last FY)-6.82%
Net Interest Coverage (Annual)-28.62x
EPS Basic Excl Extra (Annual)$-0.73
Receivables Turnover (TTM)7.20x
EV / Free Cash Flow (TTM)162.39x
Total Debt / Equity (Quarterly)0.38x
EPS Incl Extra (TTM)$-2.67
Receivables Turnover (Annual)7.65x
ROI (TTM)-22.16%
P/S Ratio (TTM)3.28x
Pretax Margin (5Y Avg)-95.97%
Revenue / Share (Annual)$14.93
Tangible BV / Share (Annual)$4.78
Forward P/E56.11x
Price vs S&P 500 (52W)-53.91%
P/E Ratio (TTM)1216.10x
Year-to-Date Return-60.03%
5-Day Price Return9.89%
EPS Normalized (Annual)$-0.73
ROA (5Y Avg)-42.92%
Net Profit Margin (Annual)-4.92%
Month-to-Date Return-17.33%
Cash Flow / Share (TTM)$-19.03
EBITD / Share (Annual)$-0.31
Operating Margin (Annual)-3.06%
LT Debt / Equity (Annual)0.16x
P/CF (TTM)70.63x
ROI (5Y Avg)-67.07%
P/E Excl Extra (TTM)1216.10x
LT Debt / Equity (Quarterly)0.38x
EPS Basic Excl Extra (TTM)$-2.67
P/TBV (Quarterly)17.23x
P/B Ratio (Annual)12.20x
Inventory Turnover (TTM)10.82x
Pretax Margin (TTM)-17.50%
Book Value / Share (Annual)$10.54
Price vs S&P 500 (13W)-45.86%
Beta2.00x
P/FCF (Annual)101.93x
Revenue / Share (TTM)$15.09
ROE (TTM)-27.50%
52-Week Low$32.21
vGradeF
gGradeB
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.28est. -0.01
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.15
4.23
4.23
4.23
Industry Peers — Health Services(21)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
WGSGeneDx Holdings Corp. Class A Common Stock | F | B | D | $52.00 |
| LFSTLifeStance Health Group, Inc. Common Stock | D | B | B | $7.94 |
| PRVAPrivia Health Group, Inc. Common Stock | D | B | D | $21.31 |
| PNTGThe Pennant Group, Inc. Common Stock | D | B | B | $32.00 |
| OMDAOmada Health, Inc. Common Stock | D | A | B | $18.38 |
| INNVInnovAge Holding Corp. Common Stock | D | C | B | $7.30 |
| USPHUS Physical Therapy Inc | C | C | D | $62.53 |
| TALKTalkspace, Inc. Common Stock | F | B | B | $5.23 |
| SRTAStrata Critical Medical, Inc. Class A Common Stock | C | A | A | $6.12 |
| ALPSALPS Group Inc Ordinary Share | — | — | C | $0.73 |
| PIIIP3 Health Partners Inc. Common Stock | A | C | B | $12.91 |
About
GeneDx Holdings develops exome and genome sequencing technologies for diagnosing rare and ultra-rare pediatric genetic disorders. The company addresses a growing market opportunity as genetic testing becomes the standard diagnostic approach, enabling earlier diagnoses and improved patient outcomes. With a core business in pediatric and rare disease diagnostics, GeneDx is expanding into data and information services as precision medicine adoption accelerates.